Weedie


Home / Newswire

v1.0.0
Home
Stocks
Warrants
Heatmap
Newswire
Shorts
Halts
Licenses

Weedstocks Newswire Feed

Weedstocks news RSS feed

CEO of Agrios Global Holdings Ltd. Presenting at The Advantage Strategy and Financial Conference June 14, 2019, in Vienna, Austria

2019-06-10 09:00:10

VANCOUVER, June 10, 2019 /CNW/ - Agrios Global Holdings Ltd. (CSE: AGRO) (OTCQB: AGGHF) (FSE: ØSA - WKN-A2N62K) ("Agrios" or the "Company") is pleased to announce that Chris Kennedy, President & CEO of Agrios will be presenting at the Advantage Strategy and Financial Conference (ASFC) on Friday June 14, 2019, in Vienna, Austria.

The ASFC, presented by Donau Invest Beteiligungs GmbH, and sponsored by GBC AG, is an invitation only event attended by institutional investors, portfolio managers, asset managers, family offices and high net worth individuals. The conference showcases international companies with innovations in technology in many sectors including agri-tech, biotech and medical/pharmaceutical applications and products.

Agrios is one of several presenters recognized for their development of ground-breaking technologies and products in the areas of agri-tech applications and data analytics that have been invited to present at the conference. Agrios, has developed and employs proprietary data analytics driven technology for use in aeroponic cultivation, which permits the replication of exact growing conditions to produce consistent premium quality crops and yields at a cost-effective price point.

Agrios' aeroponic cultivation technology is currently utilized in the cannabis sector where purity and consistency of product have become paramount for establishing global standards for measuring and prescribing doses of therapeutic cannabis derivatives. As the future potential of cannabis in the medical sector is becoming a central topic, both in the US and Europe, it is likely that standardization regulations will be enacted to ensure that patients receive pure, high quality cannabis-based medications throughout their treatment regimes.

Other innovators presenting at the ASFC  include Hookipa Pharma Inc. (NASDAQ: HOOK) a biopharmaceutical company developing a new class of immuno-therapeutics, Marinomed Biotech AG (WB: MARI) which focuses on the development of pharma products based on patent-protected technology platforms, and Accanis, a developer of  innovative drug therapeutics using mRNA for the treatment of common, localized diseases.

...

Read more


MARICANN GROUP INC. Announces Intent to Change Name to Wayland Group Corporation

2018-09-24 12:00:00

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE: MARI) (OTCQB: MRRCF) (FRANKFURT:75M) (“Maricann” or the "Company") today announced that it intends to change its name to Wayland Group Corp. In the interim, the Company expects to commence operating through its subsidiaries under the business name “Wayland Group”. In anticipation of the proposed name change, the Company has also announced that, effective September 25, 2018, its ticker symbol on the Canadian Securities Exchange will be “WAYL”.

The corporate renaming to Wayland Group supports the Company’s ongoing global expansion and development of both medical and non-medical consumer brands. The Company’s leadership team remains committed to foundational values of superior quality and world-class innovation at this milestone for the organization.

“Our roots in medical cannabis establish us as leaders on the world stage and the tremendous work our team has done building our production facilities, entering into provincial supply agreements and cultivating European partnerships has put us in this extraordinary position that we’re in today,” said Ben Ward, CEO of the Company. “The new name reflects the more expansive portfolio that we’ve built and the direction that we’re heading as a global cannabis company.”

The Company’s innovations include their purpose-built, high-tech production facilities in Langton, Ontario and licensing of product technologies such as VESIsorb®, a cannabidiol absorption technology. The Company’s recently launched recreational cannabis brand, Kiwi solidifies its customer needs-driven philosophy.

The proposed change in name to Wayland Group Corp. is subject to certain conditions, including approval of the Company’s shareholders, which the Company intends to seek at its next meeting of shareholders expected to be held later this year.

...

Read more


REPEAT - Maricann Launches Kiwi - Simplifying Cannabis for Recreational Consumers

2018-09-17 12:00:00

Maricann debuts its first recreational brand, anchored in the idea of simplicity

TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (the "Company") through its wholly-owned subsidiary Maricann Inc. proudly announces the launch of Kiwi - a straightforward, modern approach to cannabis and the first from the Company’s House of Brands - available to Canadian consumers of legal age on October 17, 2018.

Maricann is launching Kiwi as a brand designed to help Canadians learn and experience the product in a straightforward, simple and “jargon-free” way. Rather than launching with technical strains that might confuse new consumers, Kiwi will debut four variants that are easy to follow, regardless of background or expertise. Available in dried flower formats, Kiwi’s simple naming system consists of White Feather (High CBD), Hawke’s Bay (Balanced), Nelson’s Blue (Mid THC) and Flightless Bird (Mid-High THC), which are playful takes on Kiwi’s New Zealand-inspired name. Each strain will deliver reliable, consistent sensations that are easy to enjoy.

“We’re in the middle of a rapidly growing industry; one that has sparked a lot of curiosity among consumers. We’ve built Kiwi to streamline the information and clutter of products - so that cannabis is accessible to a wider public and Canadians can make smart, informed decisions on where we fit in their wellness routine and lifestyle,” said Geoff Kosar, Vice President of Sales & Marketing. “At its core, Kiwi is a celebration of the simple pleasures, and that starts with simple, straightforward communications.”

Working as Kiwi’s Master Grower, industry veteran Jennifer Ayotte brings her exacting standards and dedication to delivering quality cannabis to Maricann’s state-of-the-art facilities in Langton, Ontario. “Cannabis can be simple, elegant and easy-to-understand,” said Jennifer Ayotte, Kiwi Master Grower. “When the right measures are set in place for consistency, quality and safety, it’s easier to see that what we’re really talking about are plants.”

...

Read more


Maricann Launches Kiwi - Simplifying Cannabis for Recreational Consumers

2018-09-17 04:15:00

Maricann debuts its first recreational brand, anchored in the idea of simplicity

TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (the "Company") through its wholly-owned subsidiary Maricann Inc. proudly announces the launch of Kiwi - a straightforward, modern approach to cannabis and the first from the Company’s House of Brands - available to Canadian consumers of legal age on October 17, 2018.

Maricann is launching Kiwi as a brand designed to help Canadians learn and experience the product in a straightforward, simple and “jargon-free” way. Rather than launching with technical strains that might confuse new consumers, Kiwi will debut four variants that are easy to follow, regardless of background or expertise. Available in dried flower formats, Kiwi’s simple naming system consists of White Feather (High CBD), Hawke’s Bay (Balanced), Nelson’s Blue (Mid THC) and Flightless Bird (Mid-High THC), which are playful takes on Kiwi’s New Zealand-inspired name. Each strain will deliver reliable, consistent sensations that are easy to enjoy.

“We’re in the middle of a rapidly growing industry; one that has sparked a lot of curiosity among consumers. We’ve built Kiwi to streamline the information and clutter of products - so that cannabis is accessible to a wider public and Canadians can make smart, informed decisions on where we fit in their wellness routine and lifestyle,” said Geoff Kosar, Vice President of Sales & Marketing. “At its core, Kiwi is a celebration of the simple pleasures, and that starts with simple, straightforward communications.”

Working as Kiwi’s Master Grower, industry veteran Jennifer Ayotte brings her exacting standards and dedication to delivering quality cannabis to Maricann’s state-of-the-art facilities in Langton, Ontario. “Cannabis can be simple, elegant and easy-to-understand,” said Jennifer Ayotte, Kiwi Master Grower. “When the right measures are set in place for consistency, quality and safety, it’s easier to see that what we’re really talking about are plants.”

...

Read more


Maricann announces shipment of CBD Capsules in Germany

2018-09-14 12:42:04

TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce its first shipment of Mariplant CBD capsules to German pharmacies.

On September 12th, 2018 Maricann shipped the first batch of Mariplant CBD capsules to be sold in Munich and the Greater Munich region followed by a shipment on September 14th, 2018 to the Greater Cologne region.

The delivery of this initial order of Mariplant CBD capsules marks the next step in Maricann’s European strategy to supply quality, differentiated products to European markets. German consumers will now be able to purchase the product online (www.mariplant.de) and at their local pharmacy. The Company plans a larger scale roll out of pharmacy distribution across Germany in the coming weeks and months.

The first shipment of capsules included Maricann’s differentiated CBD gel capsules that include the patent protected VESIsorb®. VESIsorb® is Maricann’s world class drug delivery technology that allows the Company to produce a superior product to the fast-growing European CBD market at a competitive price.

As stated in previous communications, VESIsorb® has been used in a number of fat soluble pharmaceuticals and nutraceuticals for over 30 years to increase absorption and efficacy. In November of 2017, Maricann purchased the rights for use of the VESIsorb® technology in all cannabis products (see press release dated August 22, 2017). This will allow the Company to develop a full suite of products ranging from finished dose pharmaceuticals to functional beverages while maintaining quality, predictable dosing, and consistent efficacy.

...

Read more


Maricann Group Inc. Comments on Recent Market Activity

2018-09-06 21:00:00

TORONTO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Maricann” or the “Company") wishes to make the following statements regarding recent market activity in its common shares traded on the OTCQB marketplace.

The Company became aware of certain promotional activity on its securities on September 4, 2018 upon receipt of correspondence from OTC Markets specifically related to certain promotional literature encouraging investors to purchase the Company's common shares and making certain statements regarding the potential returns on such investment, including certain promotional newsletter emails. Until being informed by OTC Markets of the promotional material, the Company was unaware of the promotional activity and remains unaware of the full nature of the promotional activity and the extent of the dissemination. It is difficult to determine whether the promotional materials resulted in any increased trading activity in the Company's common shares but the Company believes that recent increases in its share price and trading volume are industry specific as the cannabis sector and the Company's direct competitors have generally seen an increase in trading activity over the past week.

Upon reviewing the content of the material, it appears that certain of the statements and claims made were taken from the Company’s website, historical press releases and other public documents, but the Company had no editorial control over the content of the material. Furthermore, there are statements made which encourage investors to purchase the common shares of the Company, which only express the view of the authors and the Company disclaims any potentially exaggerated or misleading statements contained in the material.  In addition, the Company has determined that certain statements included in these publications related to the Company and its business might be read as misleading and/or incomplete and readers should not place undue reliance on these newsletters or websites. Specifically, the Company does not condone the use of sensational language to describe the Company’s business prospects or the growth potential of the Company’s industry. The Company does not condone any statements made regarding the urgency of investing in the Company’s common shares or any other similar statements.  Finally, the Company notes that investing in the Company’s securities involves certain risks and uncertainties which investors should review prior to making any investment decision. The Company encourages all investors to undertake proper due diligence and carefully consider all investment decisions. The Company directs potential investors to rely solely on its filings and disclosures made with Canadian securities regulators, available at www.sedar.com and as posted on the filings and disclosure page for MRRCF on the OTC Markets website at www.otcmarkets.com.

The Company routinely responds to inquiries from shareholders, potential investors, and investment analysts, and generates its own Company marketing materials. The Company paid a media service, Tycona Media, to place banner advertisements on high traffic websites for the cannabis industry, complete with images of one employee and the Company’s historic greenhouse operations.  These media slots were purchased and booked one month in advance. However, to the Company's knowledge, after due inquiry of management, neither the Company, nor any of its officers, directors, controlling shareholders or any third-party service providers have directly been involved with the creation or distribution of promotional newsletter emails or websites that make exaggerated or misleading claims related to the Company and its securities.

After due inquiry of the Company's officers, directors, controlling shareholders and third party service providers, except for two officers that engaged in a securities lending arrangement (see press release dated August 10, 2018), neither the Company, nor any of its officers, directors, and to the knowledge of the Company, any controlling shareholders or third party service providers have sold or purchased the Company's securities within the past 90 days. Such transactions were in accordance with the Company's insider trading policy and were reported with the System for Electronic Disclosure (www.SEDI.ca).

...

Read more


Maricann Enters into Non-Binding Term Sheet for Strategic Joint Venture in Italy

2018-08-28 12:00:00

TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT: 75M)(OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce that it has entered into a non-binding term sheet to form a strategic joint venture with San Martino S.S. (“San Martino”), a large scale agricultural company in the Piedmont Region of Italy, founded by Milan businessman Umberto Signorini. Pursuant to the proposed joint venture Maricann and San Martino will develop a centre of excellence for cannabis products, in conjunction with the University of Eastern Piedmont, initially producing high CBD content for the medical market, and then ultimately THC product for the European market. The formation of the joint venture remains subject to due diligence and the negotiation and execution of definitive documentation.

Federico Riboldi, Vice President, Province of Alessandria stated, “It is a true pleasure to see the start of the collaboration of Maricann with San Martino to develop a CBD and THC project here in Italy, specifically, Alessandria province. I think we have found the best combination of people to become the first CBD and THC company in Italy."

Umberto Signorini Jr. commented, “The partnership between Maricann and the Signorini Family to develop CBD products is very exciting. There are great opportunities for the cosmetic, alimentary, veterinary, pharmaceutical, and recreational sectors."

"We're proud to partner with San Martino and the Signorini family and have received unprecedented governmental support for the initiative. Our first mover advantage in cannabis from Canada has proffered the opportunity to work with established and respected groups in Europe, and now in Italy with San Martino. We will bring our world leading technology, developed in conjunction with Rockwell Automation to automate and standardize cannabis production and subsequent products, while gaining advantage from existing infrastructure in Piemonte, including biogas electricity produced from San Martino's facilities," stated Ben Ward, CEO of Maricann.

About Maricann Group Inc.

...

Read more


Maricann Reports Q2 Financial Results

2018-08-24 20:30:00

TORONTO, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT: 75M)(OTCQB:MRRCF)(“Maricann” or the “Company”) has reported its financial and operating results for the first quarter ended June 30, 2018. All figures are stated in Canadian Dollars.

“We have achieved significant supply agreements with a number of provinces to supply our cannabis products which is expected to transform into shareholder value with compelling revenue in Q4 2018, 2019 and beyond. As previously disclosed, the Company has reserved product for the recreational market commencing October 17th and its pharmacy joint initiative commencing October 1st. The Company made the conscious decision to preserve inventory to meet demand for these strategic long-term sales channels,” commented Ben Ward CEO of Maricann.

Highlights for the quarter include:

At June 30, 2018, Maricann recognized revenue of $1,157,887 and $1,758,478 for the three and six months ended June 30, 2018, respectively, as compared to $661,602 and $1,804,769 during the same periods in 2017 an increase of $496,285 or 75% for the three months ended June 30, 2018 and a decrease of $46,291 or 3% for the six months ended June 30, 2018. The increase in revenue during the three months ended June 30, 2018 compared to June 30, 2017 is primarily related to two large bulk supply orders completed during Q2 2018.

For the six-months ended June 30, 2018, cash flow used in operating activities was $19,565,941 and the Company had used cash of $35,195,964 related to investing activities. Investing activities during the period relate to the Company’s new building in Langton and other facility upgrades and the purchase of production equipment, computers and furniture as well as advancements towards investments of the German subsidiary. Cash flows provided by financing activities for the six months ended June 30, 2018 were $38,581,031. The cash provided by financing activities is primarily due to an issuance of special warrants in January 2018 which resulted in proceeds, net of issuance costs, of $37,794,030, proceeds received on exercise of stock options and warrants of $1,850,529 and offset by interest payments of $988,131 on the Company’s convertible debentures and repayment of capital leases of $75,398. Subsequent to June 30, 2018, the Company closed a private placement offering of special warrants for aggregate gross proceeds of $37,401,760. See press release dated August 10, 2018.

...

Read more


Maricann Announces Filing of Preliminary Prospectus in connection with Special Warrant Offering

2018-08-22 12:00:00

Not for dissemination or distribution in the United States or through U.S. newswire services.

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI, OTCQB:MRRCF, FRANKFURT:75M, “Maricann” or the “Company”) is pleased to announce that it has filed its preliminary prospectus in connection with its previously announced private placement of special warrants for gross proceeds of $37.4 million.

As previously disclosed, consistent with the high level of activity in the sector, the Company under the direction of the special committee of the board of directors has discussed various potential strategic transactions.  In the course of these discussions, the Company has received proposals from potential interested parties and certain of these parties have conducted due diligence in respect of the Company. The Company has not received any proposals respecting potential strategic transactions that it has determined to be acceptable and it is not currently in active discussions concerning any potential strategic transactions.  Maricann intends to continue to monitor industry developments and may have further discussions in respect of potential strategic transactions in the future, but the Company can offer no assurance that any transaction would result from any such future discussions. In addition, the Company has already disclosed various European initiatives and it continues to explore additional European opportunities and other potential business joint ventures and product supply arrangements.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 847,000 sq. ft. (78,688 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth.

...

Read more


REPEAT: Maricann’s German Hemp Harvest is Yielding Results – CBD Production

2018-08-22 11:30:00

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to provide an update to the market regarding the Company’s hemp operations in Germany.

On August 3rd, 2018, Maricann’s European nutraceutical subsidiary MariPlant, commenced the harvest of approximately 165 hectares (~405 acres) of hemp. The Company planted five approved cultivars included in the European Union list of approved hemp. This inaugural harvest utilized new proprietary harvesting and drying systems, designed to optimize yield from industrial hemp.

Maricann used German ingenuity and engineering to develop harvesting equipment that separates the upper portion of the plant from the stalk at the time of harvest in the field. This reduces labour costs and ensures the quality and integrity of the plant. The hemp flowers are then taken directly in a food grade truck to an inline drying system custom designed and manufactured in Germany for Mariplant that is capable of drying up to 50,000 kg of wet hemp flowers per day. The system then separates the flowers and remaining trim to create dry ground hemp flower, immediately ready for extraction.

Maricann test controlled the hemp harvest by selecting a 4-hectare (9,88 acres) plot for hand harvest, with similar yields and results to its automated harvesting process. Output so far exceeds expectations. From the 4-hectare plot almost 3,000 kg of dried material have been collected. Final product CBD content is expected to vary between the different strains, providing sampling for next year’s crop. Third party extraction in Germany commenced on August 21, 2018.

Mariplant continues to innovate and create technological solutions for the cannabis industry to enhance shareholder value and drive down output costs. Maricann remains committed to building a business with efficiency as a core driver, based on technological differentiation and 5S manufacturing. This focus on efficiency is highlighted at the Company’s state of the art Langton, Ontario cultivation facility, where technological advances have been made via work with Rockwell Automation. (see press release dated November 22, 2017)

...

Read more